KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Gross Margin (2016 - 2025)

Teva Pharmaceutical Industries' Gross Margin history spans 10 years, with the latest figure at 56.38% for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin fell 1676.0% year-over-year to 56.38%, compared with a TTM value of 51.8% through Dec 2025, down 120.0%, and an annual FY2025 reading of 51.79%, up 305.0% over the prior year.
  • Gross Margin for Q4 2025 was 56.38% at Teva Pharmaceutical Industries, up from 51.43% in the prior quarter.
  • The five-year high for Gross Margin was 73.14% in Q4 2024, with the low at 43.21% in Q1 2023.
  • Average Gross Margin over 5 years is 49.7%, with a median of 47.99% recorded in 2021.
  • Year-over-year, Gross Margin soared 1893bps in 2024 and then plummeted -1676bps in 2025.
  • Tracing TEVA's Gross Margin over 5 years: stood at 50.0% in 2021, then fell by -9bps to 45.57% in 2022, then grew by 19bps to 54.21% in 2023, then surged by 35bps to 73.14% in 2024, then fell by -23bps to 56.38% in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Gross Margin are 56.38% (Q4 2025), 51.43% (Q3 2025), and 50.34% (Q2 2025).